RecruitingNCT07482969

Prevalence of Symptomatic Gastroesophageal Reflux Disease in Czech Children (Czech GERDKids)

Prevalence of Symptomatic Gastroesophageal Reflux Disease in Children in the Czech Republic


Sponsor

University Hospital, Motol

Enrollment

1,000 participants

Start Date

Dec 20, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to determine the prevalence of symptomatic gastroesophageal reflux disease (GERD) in children aged 8-9 years and 12-13 years in the Czech Republic. Participants are recruited through schools and complete a web-based questionnaire assessing reflux-related symptoms. Children reporting pyrosis or regurgitation undergo a stepwise diagnostic evaluation that includes a standardized proton pump inhibitor (PPI) trial, upper endoscopy when indicated, and 24-hour pH-impedance monitoring for those with inconclusive findings. These procedures allow classification into confirmed GERD, reflux hypersensitivity, or functional pyrosis. All children undergoing diagnostic testing complete a validated quality-of-life questionnaire. The study will provide population-based prevalence estimates and evaluate symptom burden and potential risk factors associated with pediatric GERD.


Eligibility

Min Age: 8 YearsMax Age: 13 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with gastro esophageal reflux. The study is currently recruiting participants at 1 location. People eligible for this study include aged 8 Years to 13 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Motol University Hospital

Prague, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07482969


Related Trials